Dr Steven Rosenberg

Following cancer's personal vulnerabilities.

The patient's own cells.

The tumour's own clues.

A career connecting immune-cell biology with the demanding work of

building treatments. The historical results below are dated; they are

not presented as discoveries from this week.

Rhoda Baer / NCI, 24 July 2008. Public-domain photograph.

The idea that changed the question

NCI describes Steven Rosenberg as a pioneer of

effective immunotherapy for advanced cancer, including

cell transfer using tumour-infiltrating lymphocytes and

genetically modified immune cells. His work connects

recognition of a cancer target with an attempt to turn

that recognition into treatment. The contribution is

scientific and clinical: a promising mechanism must be

tested in people. [7]

A demanding treatment pathway

NCI explains that cell-transfer therapy involves

collecting immune cells, growing them in a laboratory

and returning them to the patient. TIL therapy selects

cells found within a tumour; CAR T-cell therapy modifies

cells to recognise particular targets. These approaches

are related through immune-cell treatment, but they are

not interchangeable procedures. [9]

Cell expansion can take weeks, and preparation may

include chemotherapy. The pathway therefore extends

well beyond the infusion itself. NCI notes serious

potential adverse effects and the need for specialist

care. The clinical value depends on both the chance of

benefit and the burden and risk of receiving treatment.

[9]

A milestone with its date attached

A study reported by NCI in April 2025 included 91

people with metastatic gastrointestinal cancers after

extensive prior treatment. Eight of 34 who received

selected TILs with pembrolizumab had an objective

response, compared with three of 39 receiving selected

TILs alone. These were sequential groups, not a

randomized head-to-head comparison. Serious side

effects were reported in 30% of patients receiving

selected TILs. [8]

The result supports continued investigation without

establishing that the approach will work for every solid

tumour. Response, durability, toxicity and the ability to

deliver a personalised product all belong in the next

stage of evaluation. An individual success can reveal

what is biologically possible while leaving consistency

unresolved.